ITCI News and Press, Intra-Cellular Therapies Inc. From 02/14/23

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and...

Summary TG Therapeutics, Inc. is set to launch Briumvi with an experienced in-house team. There are several factors conducive to launch success. Nevertheless, uncertainty remains. If TG Therapeutics can secure a sales/marketing partnership, the company will likely make a successful ...

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data presentations at the American College of Ne...

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming invest...

Intra-Cellular Therapies, Inc. (ITCI) Q3 2022 Earnings Conference Call November 03, 2022, 08:30 ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Co-Founder, Chairman, CEO & President Mark Neumann - EVP & Chief Co...

Intra-Cellular Therapies ( NASDAQ: ITCI ) stock rose ~11% on Thursday after the company's Q3 results beat estimates. Net loss narrowed to -$53.51, compared to -$76.91M in Q3 2021. Net product sales of bipolar depression therapy Caplyta increased +232.6...